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The epidermal growth factor receptor (EGFR) is commonly expressed in non-small-cell lung cancer (NSCLC) and promotes a host of
mechanisms involved in tumorigenesis. However, EGFR expression does not reliably predict prognosis or response to EGFR-targeted
therapies. The data from two previous studies of a series of 181 consecutive surgically resected stage I–IIIA NSCLC patients who had
survived in excess of 60 days were explored. Of these patients, tissue was available for evaluation of EGFR in 179 patients, carbonic
anhydrase (CA) IX in 177 patients and matrix metalloproteinase-9 (MMP-9) in 169 patients. We have previously reported an
association between EGFR expression and MMP-9 expression. We have also reported that MMP-9 (P¼0.001) and perinuclear
(p)CA IX (P¼0.03) but not EGFR expression were associated with a poor prognosis. Perinuclear CA IX expression was also
associated with EGFR expression (Po0.001). Multivariate analysis demonstrated that coexpression of MMP-9 with EGFR conferred a
worse prognosis than the expression of MMP-9 alone (Po0.001) and coexpression of EGFR and pCA IX conferred a worse
prognosis than pCA IX alone (P¼0.05). A model was then developed where the study population was divided into three groups:
group 1 had expression of EGFR without coexpression of MMP-9 or pCA IX (number¼21); group 2 had no expression of EGFR
(number¼75); and group 3 had coexpression of EGFR with pCA IX or MMP-9 or both (number¼70). Group 3 had a worse
prognosis than either groups 1 or 2 (P¼0.0003 and 0.027, respectively) and group 1 had a better prognosis than group 2
(P¼0.036). These data identify two cohorts of EGFR-positive patients with diametrically opposite prognoses. The group expressing
either EGFR and or both MMP-9 and pCA IX may identify a group of patients with activated EGFR, which is of clinical relevance with
the advent of EGFR-targeted therapies.
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Epidermal growth factor receptor (EGFR) is a member of the c-
erbB membrane receptor family and was first described in 1980
(Cohen et al, 1980). Epidermal growth factor receptor signalling
promotes angiogenesis, cell proliferation, tumour invasion and
inhibits tumour suppressor gene activity and apoptotic signalling
(Westermark et al, 1982; Abdollahi et al, 1999; Rosen et al, 2001;
Gildea et al, 2002; Hirata et al, 2002; Di Gennaro et al, 2003).
Recently, the clinical relevance of the EGFR has been heightened in
light of the development of the EGFR tyrosine kinase inhibitors,
Getifinib and Erlotinib and EGFR monoclonal antibodies Cetux-
imab that have been demonstrated to have antitumour activity in
solid tumours including non-small cell lung cancer (NSCLC)
(Giaccone et al, 2004; Herbst et al, 2004a,b; Lynch et al, 2004b).
Immunohistochemical studies have reported EGFR overexpres-
sion in 22–81% of NSCLC tumours depending on the antibody
used and cut point that defines overexpression (Veale et al, 1987;
Volm et al, 1993; Pfeiffer et al, 1996; Cornianu and Tudose, 1997;
Pastorino et al, 1997; Rusch et al, 1997; Fontanini et al, 1998;
Greatens et al, 1998; D’Amico et al, 1999; Fu et al, 1999; Cox et al,
2000; Ohsaki et al, 2000; Selvaggi et al, 2002; Hirsch et al, 2003;
Kanematsu et al, 2003; Mukohara et al, 2003; Onn et al, 2003). The
majority of these studies have failed to demonstrate an association
with prognosis (Table 1). This may be because EGFR activation
usually requires the binding of specific ligands prior to induction
of phosphorylation of the tyrosine domain of the receptor and
subsequent dimerisation with either another EGFR molecule or
with another member of the c-erbB family of receptors (Cohen
et al, 1981; Yarden and Ullrich, 1988; Tzahar et al, 1996). Hence,
expression of EGFR alone may not accurately represent EGFR
activity. However, coexpression of EGFR with neither its most
common dimerisation partner, C-erbB2, nor its most common
ligand, transforming growth factor (TGF) a, predict prognosis
(Rusch et al, 1997; Kanematsu et al, 2003). Despite these
observations, studies that are able to identify patients with
activated EGFR may identify patients with a poor outcome. This
contention is supported by a small study of 36 patients with
resected NSCLC tumours, which reported that phosphorylated
EGFR expression is associated with a poor prognosis (Kanematsu
et al, 2003). Therefore, coexpression of EGFR with downstream factors
may identify such patients and add credence to this hypothesis.
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was not associated with prognosis (Cox et al, 2000). However, an
important relationship was found between EGFR and matrix
metalloproteinase (MMP)-9 expression. Matrix metalloproteinase-9
is an enzyme involved in the degradation of the extracellular matrix
and increased expression was associated with a poor prognosis.
Coexpression of EGFR and MMP-9 identified a subset of patients
with a significantly worse prognosis than either EGFR or MMP-9
alone (Cox et al,2 0 0 0 ) .In vitro experiments demonstrate that EGF
stimulation of EGFR-positive NSCLC cell lines can result in the
upregulation of MMP-9 and, likewise, inhibition of EGFR in vivo
reduces tumour cell MMP-9 expression (Perrotte et al, 1999;
O’Byrne et al, 2001). These data suggest that coexpression of MMP-9
and EGFR may identify patients with activated EGFR.
Carbonic anhydrase (CA) IX is a marker of hypoxia and is
regulated by the transcription factor hypoxia-inducible factor
(HIF)-1a (Wykoff et al, 2000; Swinson et al, 2003). Expression of
CA IX is associated with a poor prognosis in NSCLC (Giatroma-
nolaki et al, 2001; Swinson et al, 2003). EGF treatment of tumour
cell lines induces HIF-1a expression and constitutively active
mutations of EGFR potentiate hypoxic induction of other targets of
HIF-1a such as VEGF (Clarke et al, 2001; Semenza, 2002).
Giatromanolaki et al reported an association between CA IX and
EGFR and we have reported an association between EGFR and
HIF-1a (Giatromanolaki et al, 2001; Swinson et al, 2004). These
data suggest that coexpression of CA IX and EGFR may also
identify patients with activated EGFR.
The aims of this study were to first update the survival data from
previous studies of EGFR, MMP-9 and CA IX in a series of
surgically resected NSCLC, assess if an association exists between
EGFR and CA IX and develop a model using EGFR and related
downstream factor expression to predict the outcome in NSCLC.
MATERIALS AND METHODS
Ethics
The Leicester locoregional ethical committee granted ethical
approval for these studies.
Patient inclusion and exclusion criteria and follow-up
A consecutive series of patients who had had NSCLC tumours
resected with curative intent were considered for entry into the two
studies. Patients were excluded if tissue from the resected
specimen was not available, if they had pathologically staged stage
IV disease or survival of less than 61 days from time of operation
so as to exclude the confounding factor of perioperative mortality
(Cox et al, 2000; Swinson et al, 2003). The final staging was based
on the findings at surgery and the histopathology report. Hospital
notes of the patients were reviewed, and if necessary, the local
cancer registries or patient’s general practitioner were contacted to
complete case follow-up.
Immunohistochemistry
The specimens had previously been evaluated for the expression of
EGFR, MMP-9 and CA IX. Standard immunohistochemical
methods were employed using the anti-EGFR mouse monoclonal
antibody (Mab) EGFR.113 (Novocastra Laboratories Ltd, New-
castle, UK) (Cox et al, 2000), anti-MMP-9 mouse Mab 56-2A4
(Chemicon International Ltd, Temecula, CA 92590, USA) (Cox
et al, 2000) and anti-CA IX antibody M75 (Gift from Professor J
Pastorek, Institute of Virology, Slovak Academy of Sciences,
Slovak Republic) (Table 2) (Swinson et al, 2003).
Interpretation
The percentage of cells staining positively in each study was
estimated using light microscopy. The cut points used to
dichotomise the series in each study were predetermined. In all,
20% plus tumour cell staining was used as a cut point to define
overexpression of EGFR (both cytoplasmic and membranous) and
MMP-9 (cytoplasmic) (Cox et al, 2000). Two independent
investigators, blinded from the other’s results interpreted the
slides and where a discrepancy was found a consensus was reached
using a double-headed microscope. In the second study, there were
three distinct patterns of CA IX staining perinuclear (p),
membranous (m) and cytoplasmic. The presence or absence of
pCA IX staining was used as a cut point, as this pattern of staining
was an infrequent observation. Greater or equal to the median
defined high mCA IX staining (Swinson et al, 2003). Two
investigators blinded from each other’s results again interpreted
the staining. A third investigator adjudicated the result where
discrepancies were found. The survival data from these studies
were reviewed and updated.
Literature search for studies investigating EGFR
expression in NSCLC
Pubmed, Embase, Medline databases, the Cochrane library and
ASCO annual meeting abstracts were searched using EGFR, NSCLC
and immunohistochemistry as key words.
Table 1 Immunohistochemical studies of EGFR expression in NSCLC
No. Staining pattern Stage Cut point Percentage overexpressed P-value EGFR antibody Refs.
169 m and c I–IIIA X20% 56% 0.17 Novacastra Labs EGFR.113 Cox et al (2000)
96 I–IIIA X20% 32% N/S Rusch et al (1997)
186 M I–IV 0%, 0o80%, X80% 14, 31, 55% 0.9 R1, Amersham Pfeiffer et al (1996)
515 I o10% 50, 47% 0.25 31G7, Triton Pastorino et al (1997)
290 I–IV 43% 0.02u Ohsaki et al (2000)
158 I–IIIA X0% 66% 0.36 Sigma 014H4819 Fu et al (1999)
77 m and c I–IV 0 +++ o0.05k EGFR1 Veale et al (1987)
121 N/S Volm et al (1993)
195 I–IIIA X45% 53%/47% 0.80 Anti-EGFR Triton Fontanini et al (1998)
408 I N/S D’Amico et al (1999)
183 M I–III Tertiles 38%/25%/37% 0.22 Zymed Labs No. 28–0005 Hirsch et al (2003)
u Cornianu and Tudose (1997)
101 I–III ++/+++ intensity X5% 35%/66% N/S Zymed Labs clone 31G7 Greatens et al (1998)
60 I–III X30% 22%/78% 0.6 Zymed Labs clone 31G7 Mukohara et al (2003)
36 I–III 81%/19% N/S Kanematsu et al (2003)
98 M I X10% 61%/39% N/S Onn et al (2003)
130 I–III X10% 37%/63% o0.01u Oncogene Ab-1 Selvaggi et al (2002)
EGFR¼epidermal growth factor receptor; S¼significant; N/S¼not significant; u associated with a poor prognosis; k associated with stage survival analysis not performed.
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The SPSS software system (SPSS for Windows Version 9.0) was
used to perform the statistical analysis. The w
2-test was used to
analyse the associations between categorical variables. A P-value of
p0.05 was used as the level of significance. Overall survival as
opposed to cancer specific mortality was used to avoid bias.
Survival curves were plotted using the Kaplan–Meier method and
a log-rank test was used to assess the statistical significance of
differences in survival. A Cox proportional-hazards regression
model was used to investigate whether coexpression of factors with
EGFR significantly worsened outcome compared to expression of
factors in isolation. A Cox proportional-hazards regression model
was also used to identify statistically significant differences in
survival and estimate hazard ratios and 95% confidence intervals
(CI). Covariables were entered into the model if Pp0.05 and
removed if PX0.1.
RESULTS
Study population
In all, 218 patients were considered for the two studies. Of these, 24
patients were excluded due to poor postoperative survival and 13
patients were excluded as they were found to have pathological
stage IV disease. Of the 181 patients, tissue was available from 179
patients for staining for EGFR expression, from 177 patients for
staining for CA IX expression and from 169 patients for staining
for MMP-9 expression. In total, there were 166 cases stained for all
three markers. Of the 166 patients available for analysis, 115
(69.3%) were male and 51 (30.7%) were female. A total of 82
(49.4%) patients had stage I, 46 (27.7%) patients had stage II and
38 patients had stage IIIA (22.9%) disease. A total of 47 (28.2%)
patients had adenocarcinoma, 101 (60.8%%) patients had squa-
mous carcinoma, 14 (8.4%) patients had large-cell carcinoma and
four (2.4%) patients had tumours that were not characterised. The
mean age at surgery was 65 years (s.d. 7.9, range 33.8–79.1).
Positive resection margins were found in 15 patients. One patient
had received adjuvant chemotherapy. Adjuvant radiotherapy was
given to 17 patients, of whom 10 were stage IIIA, six were stage II
and one was stage I.
In total, 126 (75.9%) patients had died at the time of analysis
and of these 18 (10.8%) were not cancer related. The duration of
follow-up from the time of surgery was between 5 and 10 years.
Of the 15 patients who had been excluded due to lack of
tissue, there was no statistical difference in the stage (P¼0.72),
histology (P¼0.9), sex (P¼0.56) or adjuvant radiotherapy
(P¼0.56) distribution compared to the patients used in the
survival analysis.
Associations between different patterns of CA IX staining
and EGFR
Using the w
2 test membranous carbonic anhydrase (mCA) IX and
pCA IX expression patterns were positively associated with EGFR
expression. The association between pCA IX and EGFR expression
was the strongest (Po0.001). All the pCA IX-positive tumours
expressed mCA IX. The association between the mCA IX group
and EGFR was dependent on the pCA IX-positive cases, as it was
lost when the pCA IX group was subtracted from the series
(P¼0.93) (Table 3). Perinuclear CA IX was therefore used in
survival analyses for this review.
There was a trend for a positive association between pCA IX and
MMP-9 expression (P¼0.09) (Table 3).
Survival analysis for EGFR-related variables
Survival data for EGFR, pCA IX and MMP-9 expression were
updated for the study and there was no significant change in the
Table 2 Immunohistochemistry techniques and antibodies
EGFR MMP-9 CA IX
Antigen retrieval Pressure cooking 2min Pressure cooking 2min No antigen retrieval
Blocking serum Rabbit Rabbit Human
Primary antibody Novacastra EGFR.113 Chemicon 56-2A6 M75
Dilution 1:20 1:100 1:50
Incubation Overnight 41C Overnight 41C 30min at 201C
Secondary antibody Rabbit anti-mouse Rabbit anti-mouse Goat anti-mouse Ig
Ig (Dako) Ig (Dako) (Envision Kit, Dako)
Dilution 1:400 1:400 Neat
Buffer 100mmol Tris, 300mmol NaCl TBS,
pH 7.65
100mmol Tris, 300mmol NaCl TBS,
pH 7.65
100mmol Tris, 300mmol NaCl TBS,
pH 7.65
IHC kit ABC (Dako) ABC (Dako) Envision (Dako)
Cut point for
categorical analysis
X20% X20% X5% (mCA IX)
40% (pCA IX)
Reference Cox et al (2000) Cox et al (2000) Swinson et al (2003)
EGFR¼epidermal growth factor receptor; MMP-9¼metalloproteinase-9; pCA¼perinuclear carbonic anhydrase; mCA¼membranous carbonic anhydrase.
Table 3 Frequency table for pCA IX, EGFR and MMP-9 expression
Factor Negative pCA IX Positive pCA IX v
2 P-value
EGFR (N¼176)
o20% 73 11 o0.001
X20% 58 34
MMP-9 (N¼166)
Low 61 18 0.09
High 59 28
Low mCA IX High mCA IX
EGFR (N¼176)
o20% 53 31 0.009
X20% 40 52
Low mCA IX High mCA IX
pCA IX-positive cases subtracted EGFR (N¼130)
o20% 50 22 0.79
X20% 39 19
EGFR¼epidermal growth factor receptor; MMP-9¼metalloproteinase-9;
pCA¼perinuclear carbonic anhydrase; mCA¼membranous carbonic anhydrase.
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Swinson et al, 2003). Using the log-rank test, MMP-9 (P¼0.0015)
and pCA IX (P¼0.03) were associated with a poor prognosis and
EGFR expression had no prognostic value (P¼0.72) (Figures 1–
3).
Using Cox’s regression analysis to estimate hazard ratios,
coexpression of EGFR with pCA IX, mCA IX or MMP-9 increased
the hazard ratio value and strengthened the P-value compared to
these variables alone (Table 4). By entering these variables into a
multivariate analysis model, the increase in the hazard ratio for
pCA IX and MMP-9 when coexpressed with EGFR was shown to be
significant (Tables 5 and 6). However, this was not the case for
coexpression of mCA IX.
Survival analysis for EGFR coexpression, no coexpression
and no EGFR expression
In view of the associations between pCA IX, MMP 9 and EGFR
expression, the study population was divided into three groups:
group 1 expression of EGFR in the absence of pCA IX and MMP-9;
group 2 no expression of EGFR; and group 3 coexpression of EGFR
with either pCA IX or MMP-9 or both. Using the log-rank test,
group 3 had a worse prognosis than either groups 1 or 2
(P¼0.0003 and 0.027, respectively) and group 1 had a better
prognosis than group 2 (P¼0.036) (Figure 4) (Cox’s regression
analysis, Table 7). Using the w
2 test, the pattern of EGFR expression
(membranous, cytoplasmic or mixed) did not differ between the
groups.
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Figure 1 Kaplan–Meier survival curve and log-rank P-value for MMP-9
expression in NSCLC.
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Figure 2 Kaplan–Meier survival curve and log-rank P-value for pCA IX
expression in NSCLC.
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Figure 3 Kaplan–Meier survival curve and log-rank P-value for EGFR
expression in NSCLC.
Table 4 Univariate survival of EGFR-related biological variables using
Cox’s regression analysis
Prognostic factor N Hazard ratio 95% CI P-value
EGFR
o20% 86 1 0.64
X20% 93 1.08 0.77–1.51
179
MMP-9
o20% 80 1 0.001
X20% 89 1.79 1.26–2.55
169
EGFR/MMP-9 coexpression
 ve 61 1.00 o0.0001
+ve 107 2.19 1.54–3.1408
168
pCA IX
Positive 46 1.0 0.044
Negative 131 1.50 1.03–2.19
177
EGFR/pCA IX coexpression
 ve 142 1 0.003
+ve 34 1.86 1.24–2.80
176
EGFR¼epidermal growth factor receptor; MMP-9¼metalloproteinase-9;
pCA¼perinuclear carbonic anhydrase; 95% CI¼95% confidence intervals.
Table 5 Cox’s regression model for EGFR/MMP-9 coexpression
Variable Harzard ratio 95% CI P-value
MMP-9
o20% 1.0 0.792
X20% 0.93 0.54–1.59
EGFR
o20% 1.0 0.015
X20% 0.52 0.31–0.88
MMP-9/EGFR coexpression
Negative 1.0 o0.001
Positive 3.55 1.73–7.26
EGFR¼epidermal growth factor receptor; MMP-9¼metalloproteinase-9; 95%
CI¼95% confidence intervals.
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The clinicopathological factors, stage, gender, positive margins
and the use of adjuvant radiotherapy, were entered into a
multivariate model with the three groups. Stage, gender and
Epidermal growth factor receptor groupings were independent
prognostic variables (Table 8).
DISCUSSION
EGFR expression was closely associated with CA IX expression in
agreement with the study by Giatromanolaki et al We have
previously reported two important patterns of CA IX staining in
NSCLC, mCA IX, which has been proposed to be a marker of
tumour cell hypoxia and pCA IX that is associated with a poor
prognosis (Swinson et al, 2003). pCA IX was closely related to the
mCA IX group as all pCA IX tumour cells expressed mCA IX and
the majority of pCA IX positive cases (42 of 46) had high mCA IX
expression. The association between EGFR and pCA IX was
stronger than between mCA IX and EGFR. The latter relationship
appeared to be dependent on the former as when the pCA IX
subgroup was subtracted from the series the relationship between
mCA IX and EGFR was lost. When EGFR was coexpressed with
pCA IX, a worse prognosis was observed than when either of these
factors were expressed on their own, hence mirroring the
relationship between MMP-9 and EGFR (Cox et al, 2000). As
such, a model was developed where the series was split into three
groups. The first group expressed EGFR alone; the second did not
express EGFR and the third expressed EGFR with either MMP-9 or
pCA IX or both. The prognosis of the third group was the worst,
whereas the prognosis of the first was the best.
The polarisation of prognosis depending on whether or not
EGFR is coexpressed with related factors provides grounds for
the hypothesis that coexpression of EGFR with either MMP-9
or pCA IX or both represents patients with activated EGFR.
This hypothesis explains the differences in prognosis between
group 3 and the other two groups. This hypothesis is also
supported by a small study that has reported that phosphorylated
EGFR is associated with a poor prognosis in NSCLC (Kanematsu
et al, 2003).
The difference between groups 1 and 2 is less easily explained.
One explanation could be that some patients in group 2 expressed
pCA IX and MMP-9, both markers of a poor prognosis, whereas by
definition no patients in group 1 expressed these factors. However,
subtraction of patients with either MMP-9 or pCA IX or both
expression from group 2 did not alter the survival difference
between the two groups (data not shown).
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Figure 4 Survival curves for EGFR expression alone (group 1), EGFR
negative (group 2) and coexpression of EGFR with either MMP-9 or CA IX
or both (group 3).
Table 6 Cox’s regression model for EGFR/pCA IX coexpression
Variable Hazard ratio 95% CI P-value
pCA IX
Negative 1.0 0.781
Positive 0.90 0.42–1.89
EGFR
o20% 1.0 0.172
X20% 0.75 0.50–1.13
pCA IX/EGFR coexpression
Negative 1.0 0.05
Positive 3.55 1.0–5.85
EGFR¼epidermal growth factor receptor; pCA¼perinuclear carbonic anhydrase;
95% CI¼95% confidence intervals.
Table 7 Cox’s regression analysis for pCA IX, MMP-9 and EGFR
coexpression
Hazard ratio 95% CI P-value
No EGFR expression (N¼21)
1.0 0.0002
EGFR only (N¼75)
0.49 0.93–0.26 0.031
EGFR/MMP-9 or pCA IX coexpression (N¼70)
3.25 1.70–6.20 0.0004
EGFR¼epidermal growth factor receptor; MMP-9¼metalloproteinase-9;
pCA¼perinuclear carbonic anhydrase; 95% CI¼95% confidence intervals.
Table 8 Multivariate analysis of clinicopathological variables and EGFR
groupings
Number Variable Hazard ratio 95% CI P-value
82 Stage 1 1.0 0.001
46 Stage 2 1.55 1.02–2.37 0.04
38 Stage 3A 2.26 1.47–3.49 0.0002
51 Female 1.0
115 Male 1.76 1.17–2.66 0.007
21 EGFR only 1.0 0.0003
75 No EGFR 2.11 1.1–4.08 0.025
70 EGFR coexpression 3.26 1.69–6.27 0.0004
EGFR¼epidermal growth factor receptor; 95% CI¼95% confidence intervals.
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EGFR may stimulate proapoptotic pathways. Recent work has
shown that tumour cell lines expressing high levels of EGFR may
undergo apoptosis, particularly following exposure to EGF.
Increasing the level of EGFR expression in a variety of cell
types predictably leads to apoptosis, a process that requires an
active tyrosine kinase but not EGFR autophosphorylation sites
(Gulli et al, 1996; Hognason et al, 2001). Further clinical evidence
for a beneficial effect has been observed in patients receiving
cisplatin chemotherapy for advanced NSCLC, where EGFR
expression has been associated with a better prognosis (Bailey
et al, 2004).
In summary, we have demonstrated an association between
EGFR and different patterns of CA IX expression and have
previously demonstrated a similar relationship between EGFR and
MMP-9. We have hypothesised that cases with coexpression of
EGFR with either MMP-9 or pCA IX or both represent cases
with activated EGFR. Hence, promoting an aggressive NSCLC
phenotype. By developing an assay to select cases with activated
EGFR, a cohort of patients may be identified that are highly
responsive to anti-EGFR therapy. Such studies are under way
using specimens collected from the large number of clinical trials
exploring EGFR-targeted therapies in NSCLC (Lynch et al, 2004a;
Paez et al, 2004). The implications of such a finding may have great
clinical benefits.
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